口腔黏膜下纤维性变的临床治疗研究进展

王凤凤; 王涛; 李传真

doi:10.16766/j.cnki.issn.1674-4152.002558

口腔黏膜下纤维性变的临床治疗研究进展

doi: 10.16766/j.cnki.issn.1674-4152.002558

1.
海南医学院口腔医学院，海南海口 570000
2.
海南省人民医院口腔科，海南海口 570000

基金项目:

国家自然科学基金项目 81460105

国家自然科学基金项目 81960199

详细信息

通讯作者:
王涛，E-mail: 1293379391@qq.com

中图分类号: R781.59
计量
- 文章访问数: 231
- HTML全文浏览量: 320
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-01
- 网络出版日期: 2022-09-23

Progress in the clinical treatment of oral submucosal fibrosis

1.
School of Stomatology, Hainan Medical University, Haikou, Hainan 570000, China

摘要

摘要: 口腔黏膜下纤维性变(oral submucosal fibrosis, OSF)是一种上皮萎缩、黏膜固有层和黏膜下层中胶原纤维过度堆积及变性、微血管质量改变的慢性口腔黏膜疾病。早期无症状，之后逐渐表现为张口受限、黏膜发白僵硬无弹性、进食烧灼感尤其进食辛辣等刺激性食物时症状加重，个别患者表现为口干、咀嚼言语味觉功能减退。OSF具有恶变为口腔癌的倾向，癌变率高达7%~30%，因此，WHO和国际癌症研究中心(IARC)将其纳入口腔潜在恶性病种的队列中。OSF对患者生活及精神有双重的折磨。早期对轻度OSF患者进行干预，减缓甚至终止疾病的发展变得尤为重要。OSF的防治一直是国内外学者研究的重点，近年来，人们不断尝试各种药物、高压氧及手术等方式方法探索更有效的预防和治疗OSF方法，同时对OSF发病机制的研究不断深入。在药物方面主要围绕姜黄、丹参、芦荟、胎盘提取物等，在物理治疗方面集中于高压氧治疗，同时探索各种手术术式，兼顾口腔功能及美观修复术后缺损。目前OSF治疗效果不太理想，尚未发现明确的根治疗法，对症实施个性化治疗、缓解临床症状与体征，依然是治疗OSF的主要方式。现综合国内外近年来针对OSF的治疗措施，从药物治疗、物理治疗及手术治疗三方面阐述各种治疗措施研究进展，旨在为口腔科医生临床治疗OSF提供思路和依据。
- 口腔黏膜下纤维性变 /
- 药物治疗 /
- 物理治疗 /
- 手术治疗
Abstract: Oral submucosal fibrosis (OSF) is a chronic oral mucosal disease characterised by epithelial atrophy, excessive accumulation and degeneration of collagen fibres in the lamina propria and submucosa and changes in microvascular quality. It has no symptoms at the early stage. However, symptoms gradually manifest including limited mouth opening; white, stiff and inelastic mucosa; burning sensation whilst eating, especially spicy and other stimulating foods; dry mouth; and functional decline in chewing, speech and taste. OSF has a tendency to become oral cancer (7%-30%). Therefore, WHO and IARC included in the queue of potential oral malignant diseases. It's a double whammy to the patient's life and spirit. Early intervention in mild OSF patients to slow down or even stop the development of the disease has become particularly important. The prevention and treatment of OSF have been the focus of scholars in China and abroad. In recent years, researchers have been trying to explore more effective methods of prevention and treatment of OSF by means of drug therapy, hyperbaric medicine and surgical treatment. At the same time, the study of OSF pathogenesis continues to deepen. In medicine mainly around Curcuma Longa, Salvia Miltiorrhiza, aloe, placenta extract and so on, in the physiotherapy focus on Hyperbaric medicine, whilst exploring a variety of surgical procedures, both oral function and aesthetic repair of postoperative defects. At present, the effect of OSF is not good, and no definite radical therapy has been found. Individualised treatment and relief of clinical symptoms and signs are still the main ways to treat OSF. In this paper, we summarise the research progress of the treatment of OSF from three aspects of drug therapy, physical therapy and operation therapy to provide a basis for the clinical treatment of OSF by stomatologists.
- Oral submucosal fibrosis /
- Medication /
- Physiotherapy /
- Surgical operation

HTML全文

参考文献(36)

[1]	翦新春, 高兴. 口腔黏膜下纤维性变的病因、致病机理、诊断与治疗[J]. 口腔疾病防治, 2021, 29(4): 217-225. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYB202104002.htm JIAN X C, GAO X. Etiology, pathogenesis, diagnosis and treatment of oral submucous fibrosis[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(4): 217-225. https://www.cnki.com.cn/Article/CJFDTOTAL-GDYB202104002.htm
[2]	PENG Q, LI H Y, CHEN J, et al. Oral submucous fibrosis in Asian countries[J]. J Oral Pathol Med, 2020, 49(4): 294-304. doi: 10.1111/jop.12924
[3]	杨博, 符梦凡, 唐瞻贵. 槟榔碱及机械刺激构建大鼠口腔黏膜下纤维化模型[J]. 华西口腔医学杂志, 2019, 37(3): 260-264. https://www.cnki.com.cn/Article/CJFDTOTAL-HXKQ201903008.htm YANG B, FU M F, TANG Z G. Rat model with oral submucous fibrosis induced by arecoline and mechanical stimulation[J]. West China Journal of Stomatology, 2019, 37(3): 260-264. https://www.cnki.com.cn/Article/CJFDTOTAL-HXKQ201903008.htm
[4]	李辉莉, 方厂云, 苏征. 槟榔碱对颊黏膜成纤维细胞增殖及迁移的影响[J]. 国际口腔医学杂志, 2020, 47(1): 32-36. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKQ202001009.htm LI H L, FANG C Y, SU Z. Effects of arecoline on proliferation and migration of human buccal mucosal fibroblasts in vitro[J]. International Journal of Stomatolog, 2020, 47(1): 32-36. https://www.cnki.com.cn/Article/CJFDTOTAL-GWKQ202001009.htm
[5]	JAIN A, TANEJA S. Oral submucous fibrosis in pediatric patients: A systematic review and protocol for management[J]. Int J Surg Oncol, 2019, 2019: 3497136.
[6]	Al-MAWERI S A. Efficacy of curcumin for management of oral submucous fibrosis: A systematic review of randomized clinical trials[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 127(4): 300-308. doi: 10.1016/j.oooo.2019.01.010
[7]	ZHANG L, TAN J, LIU Y P, et al. Curcumin relieves the arecoline-induced fibrosis of oral mucosal fibroblasts via inhibiting HIF-1α/TGF-β/CTGF signaling pathway: An in vitro study[J]. Toxicol Res (Camb), 2021, 10(3): 631-638. doi: 10.1093/toxres/tfab046
[8]	LANJEKAR A B, BHOWATE R R, BAKHLE S, et al. Comparison of efficacy of topical curcumin gel with triamcinolone-hyaluronidase Gel individually and in combination in the treatment of oral submucous fibrosis[J]. J Contemp Dent Pract, 2020, 21(1): 83-90. doi: 10.5005/jp-journals-10024-2726
[9]	刘爱丽, 闫振峰, 毛远兴. 泼尼松龙治疗口腔黏膜下纤维性变的临床效果观察[J]. 北京口腔医学, 2021, 29(2): 93-96. https://www.cnki.com.cn/Article/CJFDTOTAL-BJKX202102010.htm LIU A L, YAN Z F, MAO Y X. Clinical effect of prednisolone in the treatment of oral submucous fibrosis[J]. Beijing J Stom, 2021, 29(2): 93-96. https://www.cnki.com.cn/Article/CJFDTOTAL-BJKX202102010.htm
[10]	肖婷, 唐瞻贵. 治疗口腔黏膜下纤维性变常用中药和西药的研究进展[J]. 口腔疾病防治, 2021, 29(11): 771-775. doi: 10.12016/j.issn.2096-1456.2021.11.008 XIAO T, TANG Z G. Research progress in the treatment of oral submucous fibrosis with traditional Chinese medicine and Western medicin[J]. Journal of Prevention and Treatment for Stomatological Diseases, 2021, 29(11): 771-775. doi: 10.12016/j.issn.2096-1456.2021.11.008
[11]	LIU J, CHEN F, WEI Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis[J]. Oral Dis, 2018, 24(5): 706-716. doi: 10.1111/odi.12715
[12]	SADAKSHARAM J, MAHALINGAM S. Evaluation of oral pentoxifylline in the management of oral submucous fibrosis: An ultrasonographic study[J]. Contemp Clin Dent, 2017, 8(2): 200-204. doi: 10.4103/ccd.ccd_1192_16
[13]	KHOLAKIYA Y, JOSE A, RAWAT A, et al. Surgical management of oral submucous fibrosis with "Seagull-nasolabial flap" combined with short-term oral pentoxifylline for preventing relapse[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(5): 512-516. doi: 10.1016/j.jormas.2019.12.015
[14]	张丽, 龙卉, 段开文. 芦荟在口腔临床医学应用中的研究新进展[J]. 口腔医学, 2017, 37(3): 285-288. https://www.cnki.com.cn/Article/CJFDTOTAL-KQYX201703025.htm ZHANG L, LONG H, DUAN K W. New research progress of Aloe vera in dental clinical application[J]. Stomatology, 2017, 37(3): 285-288. https://www.cnki.com.cn/Article/CJFDTOTAL-KQYX201703025.htm
[15]	SÁNCHEZ M, GONZÁLEZ-BURGOS E, IGLESIAS I, et al. Pharmacological update properties of aloe vera and its major active constituents[J]. Molecules, 2020, 25(6): 1324. doi: 10.3390/molecules25061324
[16]	MAJUMDER R, DAS C K, MANDAL M. Lead bioactive compounds of Aloe vera as potential anticancer agent[J]. Pharmacol Res, 2019, 148: 104416. DOI: 10.1016/j.phrs.2019.104416.
[17]	KUMAR R, SINGH A K, GUPTA A, et al. Therapeutic potential of Aloe vera-A miracle gift of nature[J]. Phytomedicine, 2019, 60: 152996. doi: 10.1016/j.phymed.2019.152996
[18]	ANURADHA A, PATIL B, ASHA V R. Evaluation of efficacy of aloe vera in the treatment of oral submucous fibrosis-a clinical study[J]. J Oral Pathol Med, 2017, 46(1): 50-55. doi: 10.1111/jop.12463
[19]	PIYUSH P, MAHAJAN A, SINGH K, et al. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial[J]. Oral Dis, 2019, 25(1): 73-79. doi: 10.1111/odi.12947
[20]	TP B, T A G, VARGHESE M, et al. Evaluation of therapeutic efficacy of different treatment modalities in oral submucous fibrosis: A comparative study[J]. J Contemp Dent Pract, 2019, 20(3): 390-394. doi: 10.5005/jp-journals-10024-2527
[21]	DATARKAR A, AKARE A, TAYAL S. Efficacy of prednisolone mouthwash in management of grade Ⅲ oral submucous fibrosis: A newer drug regimen[J]. J Maxillofac Oral Surg, 2020, 19(4): 532-538. doi: 10.1007/s12663-019-01248-3
[22]	郭锦材, 谢辉. 天然药物提取物治疗口腔黏膜下纤维性变的临床研究进展[J]. 临床口腔医学杂志, 2018, 34(11): 692-695. doi: 10.3969/j.issn.1003-1634.2018.11.016 GUO J C, XIE H. Clinical research progress of natural drug extracts in the treatment of oral submucosal fibrosis[J]. J Clin Stomatol, 2018, 34(11): 692-695. doi: 10.3969/j.issn.1003-1634.2018.11.016
[23]	KISAVE P, SHEKHAR V, BABU P S, et al. The study of placentrex and hydrocortisone as an adjunct treatment in oral submucous fibrosis[J]. J Family Med Prim Care, 2020, 9(5): 2469-2474. doi: 10.4103/jfmpc.jfmpc_268_20
[24]	李晓辉, 张永红. 糖尿病足最新治疗进展[J]. 中华全科医学, 2018, 16(6): 993-997. doi: 10.16766/j.cnki.issn.1674-4152.000272 LI X H, ZHANG Y H. Latest treatment progress of diabetes mellitus[J]. Chinese Journal of General Practice, 2018, 16(6): 993-997. doi: 10.16766/j.cnki.issn.1674-4152.000272
[25]	王琰, 王靖虓, 郭倩倩, 等. 上颌骨弥漫性骨髓炎的临床诊疗及影像学分析[J]. 中华全科医学, 2021, 19(2): 232-235. doi: 10.16766/j.cnki.issn.1674-4152.001775 WANG Y, WANG J X, GUO Q Q, et al. Clinical diagnosis, treatment and imaging analysis of diffuse osteomyelitis of maxilla[J]. Chinese Journal of General Practice, 2021, 19(2): 232-235. doi: 10.16766/j.cnki.issn.1674-4152.001775
[26]	周领航, 谭劲. 高压氧联合醋酸曲安奈德注射液局部封闭治疗口腔黏膜下纤维性变的疗效及对E-钙黏蛋白、转化生长因子-β1表达的影响[J]. 中国医学创新, 2021, 18(14): 39-43. doi: 10.3969/j.issn.1674-4985.2021.14.010 ZHOU L H, TAN J. Efficacy of hyperbaric oxygen combined with triainclnolone acetonide acetate injection in the treatment of oral submucosal fibrosis and its effect on the expression of e-cadherin and transforming growth factor-β1[J]. Medical Innovation of China, 2021, 18(14): 39-43. doi: 10.3969/j.issn.1674-4985.2021.14.010
[27]	姚玉波, 李乐乐, 石琳琳, 等. 高压氧联合药物治疗口腔黏膜下纤维化的效果分析[J]. 实用医药杂志, 2020, 37(2): 130-131. https://www.cnki.com.cn/Article/CJFDTOTAL-QEYY202002013.htm YAO Y B, LI L L, SHI L L, et al. Effect of hyperbaric oxygen combined with drugs on oral submucous fibrosis[J]. Prac J Med & Pharm, 2020, 37(2): 130-131. https://www.cnki.com.cn/Article/CJFDTOTAL-QEYY202002013.htm
[28]	MESHRAM M, ANCHLIA S, SHAH H, et al. Buccal fat pad-derived stem cells for repair of maxillofacial bony defects[J]. J Maxillofac Oral Surg, 2019, 18(1): 112-123. doi: 10.1007/s12663-018-1106-3
[29]	AGRAWAL D, PATHAK R, NEWASKAR V, et al. A comparative clinical evaluation of the buccal fat pad and extended nasolabial flap in the reconstruction of the surgical defect in oral submucous fibrosis patients[J]. J Oral Maxillofac Surg, 2018, 76(3): 676.
[30]	THUKRAL H, ROY CHOWDHURY S K, NAGORI S A. Surgical management of oral submucous fibrosis using buccal fat pad: A retrospective study of 30 cases[J]. Oral Maxillofac Surg, 2018, 22(4): 403-408. doi: 10.1007/s10006-018-0721-y
[31]	SHADAMARSHAN R A, SHARMA R, GREWAL R, et al. Use of the greater palatine pedicled flap for the surgical management of trismus in oral submucous fibrosis[J]. Br J Oral Maxillofac Surg, 2021, 59(8): 888-893. doi: 10.1016/j.bjoms.2020.08.053
[32]	ULAS BALI Z, KEÇECI Y, PABUŞCU Y, et al. Anterolateral thigh flap design by using suprafascial course of the perforator[J]. Ann Plast Surg, 2020, 84(5): 550-553. doi: 10.1097/SAP.0000000000002066
[33]	GUPTA S, PIYUSH P, MAHAJAN A, et al. Fibrotomy with diode laser (980 nm) and habit correlation in oral submucous fibrosis: A report of 30 cases[J]. Lasers Med Sci, 2018, 33(8): 1739-1745. doi: 10.1007/s10103-018-2531-8
[34]	GONDIVKAR D S M, GADBAIL D A R, SARODE D S C, et al. Treatment outcomes of laser therapy in oral submucous fibrosis-a systematic review[J]. J Oral Biol Craniofac Res, 2020, 10(3): 253-258. doi: 10.1016/j.jobcr.2020.05.004
[35]	TIWARI P, BERA R N, CHAUHAN N. What is the optimal reconstructive option for oral submucous fibrosis? A systematic review and meta-analysis of buccal pad of fat versus conventional nasolabial and extended nasolabial flap versus platysma myocutaneous flap[J]. J Maxillofac Oral Surg, 2020, 19(4): 490-497. doi: 10.1007/s12663-020-01373-4
[36]	LI Y H, CHANG W C, CHIANG T E, et al. Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: A prospective study[J]. Clin Oral Investig, 2019, 23(1): 469-476. doi: 10.1007/s00784-018-2456-4